此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical Evaluation of the Adaptilens Accommodating IOL

2026年8月4日 更新者:Adaptilens, Inc.

Feasibility Clinical Evaluation of the Adaptilens Accommodating IOL

The goals of this feasibility study are to learn more about the performance of the intraocular lens (IOL), if the IOL is safe for use, and what the best surgical techniques are for implanting the IOL in patients who require correction of aphakia following phacoemulsification extraction of a senile cataract.

研究概览

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adults who are at least 21 years of age or older.
  • Scheduled to undergo primary intraocular lens implantation for the correction of aphakia following phacoemulsification extraction of a senile cataract.
  • Clear intraocular media other than cataract.
  • Potential visual acuity of 20/32 or better in both eyes after cataract removal and IOL implantation as determined by diagnostic testing or investigator's judgement.
  • Preoperative corrected distance visual acuity (CDVA) worse than 20/40 either with or without a glare source present (e.g., Brightness Acuity Tester) or scheduled for cataract removal due to significant cataract-related symptoms/complaints.
  • Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism.
  • In good general health at screening as determined by the investigator.
  • Signed written informed consent.
  • Availability, willingness, and sufficient cognitive awareness to comply with examination procedures and schedule.

Exclusion Criteria:

  • Planned secondary procedures (such as LASIK) during the term of the study; Nd YAG capsulotomy is permitted.
  • Taking systemic medications that may confound the outcome or increase the risk to the subject.
  • Ocular conditions that may predispose for future complications.
  • Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject.
  • Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes.
  • Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future CDVA loss worse than 20/40.
  • Any anterior segment pathology (anterior segment or corneal abnormalities, chronic uveitis, iritis, corneal dystrophy, pseudoexfoliation, etc.).
  • Glaucoma, glaucoma suspect or ocular hypertension, i.e., IOP > 22 mmHg.
  • Previous retinal detachment or retinal pathology, including age-related macular degeneration.
  • Diabetes, currently being treated systemically and with retinopathy.
  • Systemic or ocular disease that may prevent the patient from achieving CDVA of 20/32 or better post operatively.
  • Require chronic administration of any topical ophthalmic or systemic medication that may affect accommodation such as mydriatic, cycloplegic and myotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, anticholinergic agents.
  • CDVA of 20/32 or worse in the fellow eye not attributable to cataract.
  • Current participation in, or have participated in, an investigational study, other than this study, within the previous 60 days before the operative day.
  • Previous ocular surgery in the operative eye, including refractive surgery.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Adaptilens A-IOL Cohort
Comprised of all eyes implanted with the Adaptilens A-IOL.
This lens is accommodating.
有源比较器:Control Cohort
Comprised of all eyes implanted with the CLAREON IOL CNA0T0 Monofocal IOL
Monofocal lens

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rates of cumulative and persistent surgical related complications observed in the Adaptilens A-IOL implanted eyes, compared to threshold rates when adjusted for the type of pre-existing condition for which the subjects are being treated.
大体时间:From enrollment to the end of the study at 36 months.
Cumulative rates of cystoid macular edema, hypopyon, endophthalmitis, lens dislocated from posterior chamber, pupillary block, retinal detachment, secondary surgical intervention. Persistent rates of cornela edema at 3 months postop or later, cystoid macular edema, iritis, IOP >30 mm Hg requiring treatment.
From enrollment to the end of the study at 36 months.
Effectiveness parameter corrected distance visual acuity (CDVA) throughout the course of the study.
大体时间:Enrollment through end of the study at 36 months.
Effectiveness parameter to be evaluated is improvement in corrected distance visual acuity (CDVA).
Enrollment through end of the study at 36 months.

次要结果测量

结果测量
措施说明
大体时间
Change in uncorrected near visual acuity (UNVA) throughout the study.
大体时间:Enrollment through the end of the trial at 36 months.
Improvement in uncorrected near visual acuity (UNVA) will be evaluated as a secondary measure of visual performance.
Enrollment through the end of the trial at 36 months.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2030年12月1日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2026年5月19日

首先提交符合 QC 标准的

2026年5月22日

首次发布 (实际的)

2026年5月26日

研究记录更新

最后更新发布 (实际的)

2026年8月6日

上次提交的符合 QC 标准的更新

2026年8月4日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • ADP-FIH-001

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅